Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG-011 gel
- Development stage
- Unknown
- Lead developer
- PrimeGenX Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
PG-011 gel is a topical small molecule Janus kinase (JAK) inhibitor developed by Beijing Puqi Pharmaceutical Technology for the treatment of inflammatory skin conditions, primarily atopic dermatitis. By inhibiting the JAK-STAT signaling pathway, PG-011 modulates the activity of cytokines that drive the chronic inflammation and itching associated with atopic dermatitis. The drug is formulated as a gel for localized application to minimize systemic exposure and potential side effects. It has undergone Phase 1 clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile in healthy adults.
02
Targets
Beyond the preview
Go deeper on PG-011 gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG-011 gel.